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Pascal A. T. Baltzer, MD Matthias Dietzel, MD Purpose:
To perform a systematic review and meta-analysis to estimate the diagnostic performance of breast proton magnetic resonance (MR) spectroscopy in differentiating benign from malignant lesions and to identify variables that influence the accuracy of MR spectroscopy.
Materials and Methods:
A comprehensive search of the PubMed database was performed on articles listed until January 6, 2012. The Medical Subject Headings and text words for the terms "breast," "spectroscopy," and "magnetic resonance" were used. Investigations including more than 10 patients at 1.5 T or 3.0 T applying one-dimensional single-voxel MR spectroscopy or spatially resolved MR spectroscopy for differentiation between benign and malignant breast lesions were eligible. A reference standard had to be established either by means of histopathologic examination or imaging follow-up of 12 or more months. Statistical analysis included pooling of diagnostic accuracy, control for data inhomogeneity, and identification of publication bias.
Results:
Nineteen studies were used for general data pooling. The studies included a total of 1183 patients and 1198 lesions (773 malignant, 452 benign). Pooled sensitivity and specificity were 73% (556 of 761; 95% confidence interval [CI]: 64%, 82%) and 88% (386 of 439; 95% CI: 85%, 91%), respectively. The pooled diagnostic odds ratio (DOR) was 34.30 (95% CI: 16.71, 70.43). For breast cancers versus benign lesions, the area under the symmetric summary receiver operating characteristic curve of MR spectroscopy was 0.88, and the Q* index was 0.81. There was evidence of between-studies heterogeneity regarding sensitivity and DOR (P , .0001). No significant influences of higher field strength, postcontrast acquisition, or qualitative versus quantitative MR spectroscopy measurements were identified. Egger testing confirmed significant publication bias in studies including small numbers of patients (P , .0001).
Conclusion:
Breast MR spectroscopy shows variable sensitivity and high specificity in the diagnosis of breast lesions, independent from the technical MR spectroscopy approach. Because of significant publication bias, pooled diagnostic measures might be overestimated.
Eligibility Criteria for Study Selection
Eligibility criteria for study selection were as follows: peer-reviewed studies on human subjects applying onedimensional single-voxel spectroscopy or spatially resolved multivoxel spectroscopic imaging for differentiation of benign from malignant breast lesions. Furthermore, the applied field strength had to be 1.5 or 3.0 T to represent current technical standards Proton MR spectroscopy (specifically, hydrogen 1 MR spectroscopy) is a noninvasive examination technique for the assessment of biochemical tissue properties. The presence of a compound resonance at around 3.23 ppm is attributed to choline metabolites such as choline, phosphocholine, and glycerophosphocholine and is simply referred to as total choline (tCho). Increased levels of tCho have been detected in malignant cancers and are ascribed to an increased cellular membrane turnover (9-11). In vivo qualitative and quantitative tCho measurements have been used as a diagnostic test in the work-up of neoplastic breast lesions (12-32).
However, the clinical value of MR spectroscopy of the breast still remains unclear and is controversial. This is because of many factors, and at this point two should be discussed. First, the number of studies investigating MR spectroscopy of the breast in a clinical setting is rather low. This substantially limits the statistical power of the data published to date. Second, study designs in the present literature are heterogeneous, in terms of both technical criteria and the characteristics of the patients studied. Variations in patient characteristics and spectroscopic methodology have been described as confounders of spectroscopic results (11, 33) . Accordingly, integrating such data into clinical practice is challenging. To solve this task, there is a need for systematic control of both patient characteristics and technical specifications.
Accordingly, we performed a systematic review and meta-analysis to investigate the diagnostic performance of tCho measurements for the D ynamic contrast material-enhanced magnetic resonance (MR) imaging is the most sensitive method for detection of breast cancer (1, 2) . The high detection rate of this method for breast cancer is based on T1-weighted studies that allow the measurement of the extracellular distribution of paramagnetic contrast agents. Although cancers show a characteristically early and strong enhancement with rapid washout, substantial overlap of enhancement characteristics between benign and malignant breast lesions has been described (3, 4) . Consequently, for lesion classification in clinical practice, a combination of morphologic criteria and dynamic enhancement pattern analysis is applied (5). Morphology assessment is a subjective task and thus prone to experience-related variation and interobserver bias. Nonmass and small lesions especially frequently cause false-positive findings owing to a limited diagnostic performance of established criteria used in dynamic contrast-enhanced MR imaging (6-8). An adjunct method providing high specificity would thus be of diagnostic value.
Implication for Patient Care
n Owing to its high specificity, MR spectroscopy may be helpful for the diagnosis of breast lesions; however, owing to its lower and variable reported sensitivity, further systematic research is necessary to verify the diagnostic value of clinically applied MR spectroscopy.
Advances in Knowledge
n In a meta-analysis of 19 studies of the diagnostic performance of proton MR spectroscopy for the differentiation of malignant from benign breast lesions, the pooled overall sensitivity and specificity were 73% (556 of 761; 95% confidence interval [CI]: 64%, 82%) and 88% (386 of 439; 95% CI: 85%, 91%), respectively.
n According to our results, the diagnostic performance of MR spectroscopy was not significantly influenced by field strength, spectroscopy sequence, method of spectra analysis, study design, or quality criteria.
n We identified significant publication bias: studies including low numbers of patients reported systematically higher sensitivities for MR spectroscopy (P , .0001). 
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Results
Study Design
Twenty eligible studies were identified (12-31). A flowchart summarizing the selection process of the finally included studies is shown in Figure 1 . Study design was described as prospective in 19 studies and retrospective in one (30) study. In one study (27) Measures for the analysis of summary ROC included the area under the ROC curve (AUC) and the Q* index. Being invariant to heterogeneity, Q* is defined as the limit case, where specificity equals sensitivity (37) .
Influence factors on diagnostic accuracy were assessed by means of formal meta-regression analysis (least squares weighted by inverse variance) (38) . The parameters listed in the Data Collection and Quality Assessment section were used as covariates. P , .05 was considered to indicate a significant difference.
"Publication bias" describes a discrepancy between what is likely to be published among available results. Studies showing significant results have a higher probability of being published compared with studies showing little or nonsignificant effects. Publication bias was assessed by using a funnel plot with each study's log DOR plotted against its standard error of the estimate. Quantitative analysis for possible publication bias was in clinical breast imaging. A reference standard had to be established, either by means of histopathologic sampling or by means of imaging follow-up of at least 12 months. Not eligible were studies with fewer than 10 patients, studies investigating only malignant lesions, and studies comparing malignant lesions with benign breast parenchyma. No further restrictions were used. Titles and abstracts of search results were reviewed by two independent observers (P.A.T.B., with 10 years of experience in breast MR imaging and 6 years of experience in breast MR spectroscopy, and M.D., with 8 years of experience in breast MR imaging). A study was included if diagnostic data could be summarized in a 2 × 2 contingency table to assess true-positive, true-negative, false-positive, and false-negative findings. If an overlap between studies was identified, the more recent report was chosen to avoid data redundancy.
Data Collection and Quality Assessment
Data collection included the following parameters: publication year, study design (retrospective vs prospective), number of patients, age, number of benign and malignant lesions, lesion size, applied field strength, voxel size and spectroscopic technique, and whether spectroscopy was performed before or after contrast medium injection. Furthermore, data on how spectra were analyzed and the number and experience of observers were collected. Overall numbers of true-positive, true-negative, false-positive, and false-negative findings were extracted, and, if available, were stratified according to mass and nonmass subgroups. Study quality was assessed by both independent observers by using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool for scoring studies. This tool provides a checklist of items regarding the representativeness and methodologic quality of investigated studies. Positive scores of 14 items are added up and can vary from 0 to 14 (34) . If present, disagreement was solved by a consensus rereading of unclear points. 
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Key Parameters Extracted from the Investigated Studies not clearly described in the text (22, 23, 26, 27) (Table) . [19] [20] [21] [22] 25, 30, 31) used the signal-to-noise ratio of the tCho peak as compared with baseline noise to examine the tCho resonance, with typical thresholds greater than 2 (range, 2-4). A fully relaxed spectrum was used as an internal reference for tCho quantitation in three studies (18, 27, 29) , with cutoff values for malignancy varying between 0.1 and 2.54 mmol/kg, while one study (28) used a normalization of the tCho peak integral by the size of the interrogated voxel. In four studies (18, 19, 22, 24) , spectra were acquired before contrast medium administration, while in one study (23) , spectra were acquired twice-before and after contrast medium administration. Here we considered only postcontrast acquisitions, as sensitivity and specificity values were substantially higher. Another study (17) included a mix of pre-and 
Synthesis of General Diagnostic Performance
Individual study results-weighted summaries of sensitivity, specificity, and DORs, together with their 95% confidence intervals (CIs) are provided in Figures 2-4 . Pooled sensitivity, specificity, (Table) .
Information on who planned spectroscopic voxel placement was given in three studies (14, 21, 29) , while the number and experience of observers interpreting acquired spectra were provided by six reports (14-17,19,30). Spectra interpretation was blinded in five investigations (14-17,31), and no information regarding blinded reading was given in the remaining articles. The mean assigned QUADAS score was 11.1 (median, 11; range, 8-13) (Table) .
Synthesis of Individual Studies: Demographic Data and Lesions
Of 20 studies, 19 were used for general data pooling, as one study (16) presented a subgroup analysis (of nonmass lesions) with overlap to another study (15). In these 19 included studies, a total of 1183 patients (range, 15-189) and 1198 lesions (range, 15-189), of which 773 were malignant (range, eight to 151) and 452 were benign (range, seven to 80), were included. Age distribution was heterogeneously reported; mean age was reported in 15 studies (12-14,16, [18] [19] [20] [21] [22] [23] 25, 26, [28] [29] [30] and ranged between 44.8 and 60 years. Subgroup age demographics only were given in three studies (24, 27, 31) , median age and range were given in one study (15), and raw data on age only
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Baltzer and Dietzel (P = .017). No correlation between number of patients and specificity was observed. Studies in which MR spectroscopy was performed before contrast medium application showed relatively high sensitivity, of between 82% (nine of 11) (24) and 100% (16 of 16) (18), without reaching statistical significance (P . .05). All other investigated covariates did not show a significant influence on the diagnostic performance of MR spectroscopy.
Assessment of Publication Bias
To address publication bias, a funnel plot of the log DOR against the standard error of the estimate of the log DOR was constructed (Fig 8) . As can be seen in the funnel plot, studies of small sample size have a higher DOR than studies of a larger sample size. The Egger test confirmed the presence of publication bias (P , .0001). Use of the trim and fill method for bias correction revealed 99), respectively. There was strong evidence of between-study heterogeneity for sensitivity (I 2 = 84.5%, P , .0001). Figure 7 shows forest plots that include pooled sensitivity and specificity in nonmass lesions, revealing pooled sensitivity of 62% (34 of 55) and pooled specificity of 79% (50 of 63). There was strong evidence of between-study heterogeneity for sensitivity (I 2 = 88.3%, P , .0001). As shown in Figures 6 and 7, sensitivity and especially specificity seemed to be lower in nonmass lesions.
Factors Influencing the Diagnostic Performance of MR Spectroscopy
Meta-regression analysis identified number of patients investigated as the only significant predictor of diagnostic performance (coefficient = 20.01; standard error of the estimate = 0.0032; P = .0058). The (confounder-corrected) correlation coefficient was 0.587 between sensitivity and number of patients and DOR were 73% (556 of 761), 88% (386 of 439), and 34.3, respectively. There was strong evidence of betweenstudy heterogeneity for sensitivity (I 2 = 89.6%, P , .0001) and DOR (I 2 = 65%, P , .0001).
A summary ROC curve with AUC and Q* index data is shown in Figure 5 . The AUC and Q* index were 0.88 and 0.81, respectively.
Synthesis of Diagnostic Performance in Mass and Nonmass Subgroups
Five studies (13, 14, 17, 19, 30) included contingency table data on mass lesions and another six studies (13, 14, 16, 17, 19, 30) included data on nonmass lesion subgroups. Of the latter, only five studies were used for data pooling, as the nonmass lesion subgroup in one study (17) consisted of benign lesions only. Pooled estimates for sensitivity and specificity (Fig 6) in mass lesions were 68% (115 of 170) and 88% (87 of 
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Discussion
The present meta-analysis investigated the diagnostic performance of proton MR spectroscopy for differentiation between benign and malignant neoplastic lesions of the breast. Several quality-related issues were identified: Only 50% (10 of 20) of all studies recruited patients in a consecutive manner. Although the spectroscopic technique was described sufficiently in all articles, only 75% (15 of 20) reported assessment of basic spectroscopic quality criteria in terms of FWHM. Because peak height and FWHM are correlated, high FWHM corresponding to low B0 field homogeneity implies false-negative choline findings at spectroscopy. This is why FWHM details should be provided in any MR spectroscopy study. Furthermore, only 
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The most important consequence of the presence of publication bias for the present meta-analysis is an overestimation of the diagnostic performance of MR spectroscopy. Bias correction by the trim and fill method showed a corrected DOR of 11.53, which was lower than the original estimate of 34.3. However, even after bias correction, breast MR spectroscopy shows significant discriminatory power as a diagnostic test. A variety of spectroscopic techniques at different field strengths were used. Higher field strengths provide higher signal-to-noise ratios, and spectroscopic imaging allows spatially resolved examinations with small voxels. Although a diagnostic benefit may thus be expected, comparison with studies at 1.5 T did not reveal such an advantage yet. A diagnostic advantage of MR spectroscopy related to improvements in coil in terms of diagnostic odds ratio was found, especially in small studies. It has to be assumed that cancers investigated in small studies differed (eg, in terms of size, grade) from those in studies in larger numbers of subjects. However, this is not reflected in lesion-related data provided in the text. As no effects of technical parameters or study design on diagnostic performance of MR spectroscopy were identified, either retention of negative results or bias in malignant lesion recruitment has to be assumed. This is of interest, as it has previously been assumed that variations in methodology are a confounding factor for breast MR spectroscopy diagnostic performance (11). Using formal meta-analysis, we can reject the hypothesis of significant influences on MR spectroscopy diagnostic performance by the different methodologies used.
were not investigated in any study. The mean QUADAS score was rather high at 11.1, meaning that the investigated studies fulfilled most quality criteria. However, the issues listed above, first of all the missing statements regarding blinded spectra interpretation, have to be considered as substantial limitations.
Analysis of 1198 lesions demonstrated a consistent high pooled specificity of 88% (386 of 439) and a lower sensitivity of 73% (556 of 761). The latter showed substantial heterogeneity and varied between 42% (31 of 74) (25) and 100% (15, 18, (20) (21) (22) . As threshold effects were not significant in our analysis, further reasons seem to influence heterogeneity. Meta-regression identified a negative correlation between study size and diagnostic performance (P = .0058). Publication bias toward higher diagnostic performance 
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Baltzer and Dietzel empirical data were found to be very limited. A detrimental effect of contrast agents on MR spectroscopy has been described in both experimental and warranted to clarify especially the role of multichannel technology, higher field strength, and spectroscopic imaging in breast MR spectroscopy, as published architecture and MR imaging systems was not identified: Year of publication showed no influence on diagnostic performance. However, further study is Publication bias toward higher diagnostic performance was identified, hinting at a possible overestimation of pooled diagnostic parameters. Reporting of MR spectroscopy studies could be improved regarding study design and patient recruitment, as well as spectra acquisition and reading conditions. Data on reliability were insufficient. Standardized prospective multicenter trials providing patient-based comparisons with standard imaging procedures are warranted to clarify the use of MR spectroscopy for differential diagnosis of breast lesions.
clinical settings (42) (43) (44) . Although visual inspection of forest plots showed a relatively high sensitivity of precontrast MR spectroscopy, no statistical significance was reached, hinting at a relatively small effect regarding lesion differentiation at MR spectroscopy. However, altered tCho signal intensities after contrast medium injection have to be considered if absolute tCho quantification is performed.
Potentially, absolute tCho quantification could lead to a more standardized reading of breast spectra, enabling transfer of thresholds between institutions. The internal reference approach used by three investigated studies eliminates the influence of tumor-to-voxel ratio, voxel size, and voxel position (45) . However, water content in breast tissue is variable and may thus bias quantification results (46, 47) . In our meta-analysis, quantitative approaches did not show higher accuracy compared with qualitative spectra inspection.
It should be kept in mind that MR spectroscopy has a generally low signalto-noise ratio. Although large lesions were investigated, with 50% (10 of 20) of all studies omitting lesions smaller than 10 mm, sensitivity showed the variations described above. This fact limits the applicability of MR spectroscopy in the diagnosis of early breast cancer and generally small lesions. Although the pooled specificity of MR spectroscopy was found to be high and of little heterogeneity, the limited sensitivity of this method as identified in this meta-analysis may be detrimental for decreasing the number of false-positive findings at contrast-enhanced breast MR imaging by using MR spectroscopy, as suggested by some authors (15, 18, 20) . False-positive findings at contrast enhanced breast MR imaging are commonly encountered in small and nonmass lesions (6,7). Subgroup meta-analysis showed a similar picture, demonstrating heterogeneous diagnostic performance of MR spectroscopy in nonmass lesions. In particular, specificity was lower as compared with that for mass lesions. Although breast cancer might be detected by means of spectroscopic imaging only, single-voxel spectroscopy cannot be used for lesion
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